Nivolumab is often combined with anti-CTLA-4 antibody ipilimumab, not only for recurrent/metastatic cervical cancer in the classical CheckMate 358 (NCT02488759) but also for locally advanced cervical cancer when combined with chemoradiotherapy. The gene discussed is CTLA4; the disease is cervical carcinoma.